(COG ACCL1131) A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogenetic Hematopoietic Cell Transplantation (HCT)
Description: 

To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 days following allogeneic HCT at high-risk for IFI compared with azole (fluconazole or voriconazole) prophylaxis.

Study Number: 

NCG 237813

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01503515

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.